^
Association details:
Biomarker:No biomarker
Cancer:Marginal Zone Lymphoma
Drug:Yinuokai (orelabrutinib) (BTK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Title:

InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL

Published date:
04/20/2023
Excerpt:
InnoCare Pharma...announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in the treatment of patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).